Get the Stockscreener App
3.44
1.99%
-0.07
After Hours:
3.44
Sab Biotherapeutics Inc stock is traded at $3.44, with a volume of 609.48K.
It is down -1.99% in the last 24 hours and down -9.47% over the past month.
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
See More
Previous Close:
$3.51
Open:
$3.53
24h Volume:
609.48K
Relative Volume:
0.70
Market Cap:
$263.04M
Revenue:
$114.70K
Net Income/Loss:
$-26.49M
P/E Ratio:
-1.3947
EPS:
-2.4665
Net Cash Flow:
$-53.17M
1W Performance:
-1.99%
1M Performance:
-9.47%
6M Performance:
-19.63%
1Y Performance:
+34.90%
1-Day Range:
$3.43
$3.635
1-Week Range:
$3.43
$3.775
52-Week Range:
$1.85
$5.15
Sab Biotherapeutics Inc Stock (SABS) Company Profile
Name
Sab Biotherapeutics Inc
Sector
Industry
Phone
305-845-2813
Address
777 W 41ST ST, MIAMI BEACH
Compare SABS vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SABS
Sab Biotherapeutics Inc
|
3.44 | 268.39M | 114.70K | -26.49M | -53.17M | -2.4665 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-26 | Initiated | Rodman & Renshaw | Buy |
| Dec-19-25 | Initiated | Guggenheim | Buy |
| Sep-17-25 | Initiated | Leerink Partners | Outperform |
| May-14-25 | Resumed | H.C. Wainwright | Buy |
| Oct-09-24 | Initiated | Craig Hallum | Buy |
| Aug-28-24 | Initiated | Oppenheimer | Outperform |
| Nov-05-21 | Initiated | Chardan Capital Markets | Buy |
View All
Sab Biotherapeutics Inc Stock (SABS) Latest News
SAB Biotherapeutics Inc (SABS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
SAB Biotherapeutics Inc (SABS) Valuation: PE, PB & Fair Value Analysis - TradingKey
SABS Technical Analysis & ETF Price Forecast - Intellectia AI
SAB Biotherapeutics Inc (SABS) Balance Sheet - TradingKey
SAB Biotherapeutics Inc (SABS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
SAB Biotherapeutics Inc (SABS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
SAB Biotherapeutics Inc (SABS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
SABS|SAB Biotherapeutics Inc|Price:3.510|Chg%:-0.070 - TradingKey
SAB Biotherapeutics, Inc. Revenue Breakdown – NASDAQ:SABSW - TradingView
SAB Biotherapeutics (SABS) Slides 3.4% as Stock Tests Key Support LevelsPositive Gamma - dars.gov.et
SAB Biotherapeutics (SABS) and Breakthrough T1D Award Research Grant For SAB-142 Assessment - Yahoo Finance
SAB Biotherapeutics (SABS) Short Interest & Short Float | Updated Jul 2026 $SABS - MarketBeat
SAB Biotherapeutics (SABS) Edges Lower as Stock Tests Key Support LevelsCorrective Wave - DonanımHaber
SAB Biotherapeutics advances SAB-142 Type 1 diabetes trial - TipRanks
Breakthrough T1D Awards Grant for SAB-142 PRISE-hATG Study to Advance Type 1 Diabetes Therapies Beyond 100 Days Post-Diagnosis – Minichart - Minichart
Breakthrough T1D funds PRISE-hATG to study SAB-142 in Stage 3 type 1 diabetes - TradingView
Grant backs SAB Biotherapeutics (NASDAQ: SABS) PRISE-hATG Stage 3 T1D trial - Stock Titan
Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes - The Manila Times
Wall Street Analysts Lift SAB Biotherapeutics Stock Over Diabetes Drug - HarianBasis.co
Why Is H.C. Wainwright Bullish On SAB Biotherapeutics (SABS) With $10 Price Target? - Yahoo Finance
SAB Biotherapeutics, Inc. Warrant 2021-22.10.26 on SAB Biotherap Financial Disclosures & SEC Filings - TradingView
Price to sales forward of SAB Biotherapeutics, Inc. – NASDAQ:SABS - TradingView
SABSW Plunges to Penny Level as Biotech Warrant Faces Continued Selling PressureSupport Level Bounce - dars.gov.et
Barclays Initiates Overweight Rating on SAB Biotherapeutics, Signaling Positive Sector SentimentGross Profit Margin - dars.gov.et
Barclays Assigns Overweight Rating to SAB Biotherapeutics Inc. (SABS) - Yahoo Finance
SAB Biotherapeutics, Inc.(NasdaqCM: SABS) added to Russell 2000 Index - marketscreener.com
SAB Biotherapeutics, Inc.(NasdaqCM:SABS) added to Russell Microcap Value Benchmark Index - marketscreener.com
SAB Biotherapeutics, Inc.(NasdaqCM: SABS) added to Russell 2000 Value Benchmark - marketscreener.com
SAB Biotherapeutics, Inc.(NasdaqCM: SABS) added to Russell Microcap Index - marketscreener.com
SAB Biotherapeutics, Inc.(NasdaqCM: SABS) added to Russell 3000E Value Benchmark - marketscreener.com
SAB Biotherapeutics, Inc.(NasdaqCM: SABS) added to Russell 3000E Index - marketscreener.com
Price to sales forward of SAB Biotherapeutics, Inc. – NASDAQ:SABSW - TradingView
Price to book forward of SAB Biotherapeutics, Inc. – NASDAQ:SABSW - TradingView
Form 4 SAB Biotherapeutics Inc For: 26 June By Investing.com - Investing.com South Africa
Enterprise value to EBITDA forward of SAB Biotherapeutics, Inc. – NASDAQ:SABS - TradingView
Price to book forward of SAB Biotherapeutics, Inc. – NASDAQ:SABS - TradingView
[Form 4] SAB Biotherapeutics, Inc. Insider Trading Activity - Stock Titan
SAB Biotherapeutics, Inc. Actuals & Estimates (NASDAQ:SABS) - TradingView
SABS Forecast — Price Target — Prediction for 2027 - TradingView
Barclays initiates SAB Biotherapeutics stock at Overweight, PT $13 By Investing.com - Investing.com South Africa
Barclays Initiates SAB Biotherapeutics at Overweight With $13 Price Target - marketscreener.com
Barclays initiates SAB Biotherapeutics stock at Overweight, PT $13 - Investing.com
SAB Biotherapeutics Inc (SABS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
SABS Q1 2026 Earnings: EPS Misses Estimates as Operational Costs ClimbEPS Estimate Trend - dars.gov.et
Citi Maintains SAB Biotherapeutics(SABS.US) With Buy Rating, Maintains Target Price $11 - Moomoo
SAB Biotherapeutics (SABS) 44th Annual J.P. Morgan Healthcare Conference Summary - Quartr
SAB Biotherapeutics, Inc. 8-K SEC Filing Details for June 18, 2026: Company Information & Nasdaq Listing - Minichart
SAB Biotherapeutics Inc (SABS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
SAB Biotherapeutics shareholders elect directors and approve auditor at annual meeting - Investing.com UK
Sab Biotherapeutics Inc Stock (SABS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):